Haemophilia Forecast in 17 Major Markets 2017-2027

  • ID: 4400045
  • Report
  • 70 pages
  • Black Swan Analysis
12 % OFF
until Jan 05th 2019
1 of 3
Haemophilia in 17 Major Markets

Haemophilia is a collective term describing rare, usually inherited genetic blood coagulation disorders that lead to abnormally long bleeding at the site of wound or injury and, in severe cases, spontaneous bleeding episodes without any apparent injury. The disorders are caused by absent or insufficient activity of blood coagulation factors.

This report covers the two main types of the disease, haemophilia A (factor VIII deficiency) and B (factor IX deficiency), both of which are X-linked recessive disorders that are much more common in males, as well as acquired haemophilia, a very rare autoimmune disorder caused by abnormal immune system autoreactivity, resulting in clotting factor deficiency (usually factor VIII) and signs and symptoms similar to those of HA/HB.

This report provides the current prevalent population for haemophilia across 17 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Greece, Turkey, Russia, Japan, China, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight, sub-populations with the covered types of haemophilia, as well as several of the main symptoms and co-morbidities of haemophilia and clinical features thereof have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for haemophilia include:
  • Development of inhibitors
  • Haemophilic arthropathy
  • Reduced bone density
  • Cirrhosis
  • Hepatocellular carcinoma
This report is built using data and information sourced from the proprietary patient segmentation database. To generate accurate patient population estimates, the database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reasons to Buy:
  • Able to quantify patient populations in global haemophilia market to target the development of future products, pricing strategies and launch plans
  • Gain further insight into the prevalence of the subdivided types of haemophilia and identify patient segments with high potential
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries
  • Provide a level of understanding on the impact from specific co-morbid conditions on haemophilia prevalent population
  • Identify sub-populations within haemophilia which require treatment
  • Gain an understanding of the specific markets that have the largest number of haemophilia patients
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Comorbid Conditions / Features Associated With the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Haemophilia
Features of Haemophilia Patients
Haemophilia a Patients
Haemophilia B Patients
Acquired Haemophilia Patients
Comorbid Conditions of Haemophilia Patients
Haemophilic Arthropathy
Other Comorbid Conditions
Abbreviations Used in the Report
Other Publications
Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data & Platforms
References
Appendix

List of Tables and FiguresTable 1. Prevalence of Haemophilia, Total (000S)
Table 2. Prevalence of Haemophilia, Males (000S)
Table 3. Prevalence of Haemophilia, Females (000S)
Table 4. Patients With Haemophilia a by Sex (000S)
Table 5. Patients With Haemophilia a by Disease Severity (000S)
Table 6. Haemophilia a Patients With Development of Inhibitors, Total (000S)
Table 7. Patients With Haemophilia B by Sex (000S)
Table 8. Patients With Haemophilia B by Disease Severity (000S)
Table 9. Haemophilia B Patients With Development of Inhibitors, Total (000S)
Table 10. Patients With Acquired Haemophilia by Sex (000S)
Table 11. Haemophilia Patients With Haemophilic Arthropathy, Total (000S)
Table 12. Haemophilia Patients With Haemophilic Arthropathy by Severity, Total (000S)
Table 13. Haemophilia Patients With Haemophilic Arthropathy by Affected Joints, Total (000S)
Table 14. Haemophilia Patients With Reduced Bone Density, Total (000S)
Table 15. Haemophilia Patients With Cirrhosis, Total (000S)
Table 16. Haemophilia Patients With Hepatocellular Carcinoma, Total (000S)
Table 17. Abbreviations and Acronyms Used in the Report
Table 18. Usa Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 19. Usa Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 20. Canada Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 21. Canada Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 22. France Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 23. France Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 24. Germany Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 25. Germany Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 26. Italy Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 27. Italy Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 28. Spain Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 29. Spain Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 30. Uk Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 31. Uk Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 32. Poland Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 33. Poland Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 34. Greece Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 35. Greece Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 36. Turkey Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 37. Turkey Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 38. Russia Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 39. Russia Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 40. Japan Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 41. Japan Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 42. China Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 43. China Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 44. India Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 45. India Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 46. Australia Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 47. Australia Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 48. Brazil Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 49. Brazil Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)
Table 50. Mexico Prevalence of Haemophilia by 5-Yr Age Cohort, Males (000S)
Table 51. Mexico Prevalence of Haemophilia by 5-Yr Age Cohort, Females (000S)

Figure 1. Blood Coagulation Cascade With Fviii and Fix Marked With Blue and Red Rectangles, Respectively. (Modified from Joe D, Wikipedia.Org)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll